We are contrasting Edge Therapeutics Inc. (NASDAQ:EDGE) and Tocagen Inc. (NASDAQ:TOCA) on their profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Edge Therapeutics Inc.||N/A||0.00||N/A||-1.31||0.00|
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 represents Edge Therapeutics Inc. (NASDAQ:EDGE) and Tocagen Inc. (NASDAQ:TOCA)’s net margins, return on assets and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Edge Therapeutics Inc.||0.00%||-118.1%||-82.7%|
Edge Therapeutics Inc.’s Current Ratio and Quick Ratio are 5.6 and 5.6 respectively. The Current Ratio and Quick Ratio of its competitor Tocagen Inc. are 5.9 and 5.9 respectively. Tocagen Inc. therefore has a better chance of paying off short and long-term obligations compared to Edge Therapeutics Inc.
The Recommendations and Ratings for Edge Therapeutics Inc. and Tocagen Inc. are featured in the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Edge Therapeutics Inc.||0||0||0||0.00|
Tocagen Inc. on the other hand boasts of a $11 consensus price target and a 12.59% potential upside.
Insider & Institutional Ownership
The shares of both Edge Therapeutics Inc. and Tocagen Inc. are owned by institutional investors at 28.2% and 38.2% respectively. Insiders held 11.39% of Edge Therapeutics Inc. shares. Competitively, insiders own roughly 6.59% of Tocagen Inc.’s shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Edge Therapeutics Inc.||14.43%||4.52%||-11.61%||-45.89%||-96.93%||43.27%|
For the past year Edge Therapeutics Inc. was more bullish than Tocagen Inc.
Tocagen Inc. beats on 6 of the 10 factors Edge Therapeutics Inc.
Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.
Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The companyÂ’s lead product candidate is Toca 511 & Toca FC that is in Phase 2 portion of a randomized, controlled Phase 2/3 clinical trial for patients with recurrent high grade glioma (HGG). It is also developing Toca 511 & Toca FC in a Phase 1b clinical trial for metastatic cancers, including colorectal, pancreatic, breast, lung, melanoma, and renal. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets, such as the checkpoint protein PD-L1. Tocagen Inc. was founded in 2007 and is headquartered in San Diego, California.